C4 Therapeutics (CCCC) - News Mentions

Sign up to add (CCCC) to your portfolio and access more historical data.

00%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 0 100%
Gilead Sciences
Gilead Sciences
GILD		 1 66.7%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 0%
Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $10.50
November 7
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
November 5
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
November 5
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
November 4
C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations
November 1
Analysts’ Top Healthcare Picks: C4 Therapeutics (CCCC), Alnylam Pharma (ALNY)
October 31
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
October 30
C4 Therapeutics Advances in Protein Degradation Therapy
October 30
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
October 30
C4 Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Business Highlights Form 8 K
October 30
C4 Therapeutics GAAP EPS of -$0.35 beats by $0.05, revenue of $15.36M beats by $10.76M
October 30
C4 Therapeutics (CCCC) Q3 2024 Earnings: Revenue Surges to $15.4M, GAAP EPS Loss Narrows to $0.35
October 30
C4 Therapeutics reports Q3 EPS (35c), consensus (38c)
October 30
C4 Therapeutics files $400M mixed securities shelf
October 30
C4 Therapeutics files to sell 4.87M shares of common stock for holders
October 30
We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely
October 29

Month over Month

Est. daily news mentions.

Oct 2024 0
Sep 2024 0
Aug 2024 0
Jul 2024 0
Jun 2024 0

How often is C4 Therapeutics mentioned in the news?

C4 Therapeutics was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is C4 Therapeutics performing compared to its industry peers?

C4 Therapeutics underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of C4 Therapeutics in the last month?

C4 Therapeutics' was mentioned in fewer articles yesterday, compared to the same day last month.

Why is it important to track news mentions for C4 Therapeutics?

By monitoring mentions in the news for C4 Therapeutics, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of C4 Therapeutics, ultimately improving their investment strategies.

Sign up and get more insights on C4 Therapeutics.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact